Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHighmark Blueshield Neny Dupixent Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentHighmark Blueshield NenyPolicy N/A

    Dupixent (dupilumab) prior authorization request form coverage criteria

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Form and clinical intake questions used to request prior authorization for Dupixent (dupilumab) for multiple indications (atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, COPD, chronic spontaneous urticaria). Affects prescribing providers and prior authorization reviewers for Highmark BlueShield NE/NY membership.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyDupixent (dupilumab) prior authorization request form coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form specifying Dupixent presentation, diagnosis/ICD‑10, dosing (induction and maintenance quantity/day supply) and required provider/member details to the specified fax or mailing address.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multi-indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    indications covered on form
    4Dupixent presentations listed
    28/84requested day supply options
    kg requiredmember weight documented

    Coverage Criteria and Indication-Specific Intake

    Intake criteria per indication

    Covered when the indication-specific objective findings and prior therapy history listed on the intake form are documented; the form collects the following grouped elements per indication.

    Atopic dermatitis intake: Prescriber specialty (dermatologist, allergist, immunologist, other); therapeutic failure or intolerance to a generic topical corticosteroid and/or generic topical tacrolimus or pimecrolimus; inability to apply topical therapies due to extent of body surface area involvement; presence of severe atopic dermatitis with severely damaged skin; prior Dupixent use and whether positive clinical response was experienced

    From atopic dermatitis section of form

    Eosinophilic esophagitis (EoE) intake: Esophageal biopsy eosinophil count greater than or equal to 15 eos/hpf; clinical symptoms of esophageal dysfunction (for example dysphagia, food impaction, gastroesophageal reflux); history of EoE signs or symptoms; two or more episodes of dysphagia per week; therapeutic failure, contraindication, or intolerance to high-dose proton-pump inhibitor therapy; prior Dupixent use and, if yes, select responses (reduced symptom severity/frequency and/or histological remission <15 eos/hpf)>= 15 eos/hpf

    From EoE section of form

    Asthma intake: Baseline pre-bronchodilator FEV1; bronchodilator reversibility of at least 12% and 200 mL after albuterol; history of ≥2 asthma exacerbations requiring systemic corticosteroids in prior 12 months or ≥1 hospitalization for asthma in prior 12 months; blood eosinophil count ≥150 cells/µL; current use of daily or alternate-day oral corticosteroids (yes/no); inadequate control despite regular medium- or high-dose inhaled corticosteroid plus at least one additional controller; intent to continue ICS+controller while using Dupixent; prior Dupixent use and, if yes, select clinical responses (decreased rescue medication/oral steroid use, decreased exacerbation frequency, improved pulmonary function, reduced asthma symptoms)FEV1 reversibility >= 12% and >= 200 mL; blood eosinophils >= 150 cells/µL

    From asthma section of form

    Chronic rhinosinusitis with nasal polyposis (CRSwNP) intake: Baseline bilateral nasal polyp score (0–8) and baseline nasal congestion score (0–3); therapeutic failure, intolerance, or contraindication to an intranasal corticosteroid; therapeutic failure, intolerance, or contraindication to a 14‑day course of oral corticosteroids; prior Dupixent use and, if yes, select responses (decrease in nasal polyp score and/or nasal congestion severity)

    From CRSwNP section of form

    Prurigo nodularis intake: Prescriber specialty (dermatologist, allergist, immunologist, other); presence of at least 10 identifiable nodular lesions; therapeutic failure, intolerance, or contraindication to one generic topical corticosteroid; inability to apply topical therapies due to extent of BSA involvement; severely damaged skin; prior Dupixent use and, if yes, select responses (reduction in itch and/or reduction in number of nodules)

    From prurigo nodularis section of form

    COPD intake: Post-bronchodilator FEV1 percent predicted; blood eosinophil count; mMRC dyspnea scale score; current daily or alternate-day oral corticosteroid use; history of ≥2 moderate exacerbations treated with systemic corticosteroids and/or antibiotics in prior year or ≥1 severe exacerbation requiring hospitalization/observation >24 hours; classification as GOLD group E; inadequate symptom control despite ≥3 months of triple therapy (LAMA + LABA + ICS) or intolerance/contraindication to these agents; prior Dupixent use and, if yes, select responses (reduction in symptoms, improved exercise tolerance, delayed disease progression, reduction in exacerbations)

    From COPD section of form

    Chronic spontaneous urticaria (CSU) intake: Therapeutic failure, intolerance, or contraindication to antihistamines at maximum recommended doses (for example cetirizine, desloratadine, levocetirizine); prior Dupixent use and, if yes, whether member experienced improvement in CSU symptoms while on therapy

    From CSU section of form

    The prior authorization form collects indication-specific clinical findings and prior therapy history to support a determination that Dupixent (dupilumab) is medically necessary. For each covered diagnosis the form requests objective measures (for example, esophageal biopsy eosinophil count for EoE; pre‑ and post‑bronchodilator FEV1 and blood eosinophils for asthma; bilateral nasal polyp score for CRSwNP; mMRC score and exacerbation history for COPD) and documentation that the member has had therapeutic failure, intolerance, or a contraindication to specified prior therapies. The form also asks whether the member previously received Dupixent and, if so, to document clinical response to therapy.

    The form does not list explicit absolute exclusions. Instead, it requests documentation of contraindications or intolerance to prior therapies where relevant to the indication (for example, inability to use topical therapies due to extensive BSA or severely damaged skin for atopic dermatitis; failure/intolerance/contraindication to high‑dose PPI for EoE; failure/intolerance/contraindication to intranasal corticosteroids or a 14‑day oral corticosteroid course for CRSwNP; maximum‑dose antihistamine failure for CSU). Reviewers should base coverage decisions on the presence of the required objective findings and prior therapy history documented on the form.

    Completion of the form and any authorization determination do not guarantee payment: payment is subject to member eligibility and authorization does not guarantee payment. Providers must supply complete and accurate documentation to support medical necessity and verify member benefit coverage with the plan.

    Medication Presentations, Key Clinical Thresholds, and Supply

    Requested medication presentationsmixed
    Dupixent 200mg/1.14ml syringelisted product presentation
    Dupixent 30Omg/zml syringelisted product presentation (as printed)
    Dupixent 200mg/1.14ml penlisted product presentation
    Dupixent 300mg/2ml penlisted product presentation
    Eosinophilic esophagitis — eosinophil count threshold
    Eosinophil count threshold>= 15 eos/hpf on esophageal biopsy
    Clinical contextRequires clinical symptoms of esophageal dysfunction (e.g., dysphagia, food impaction)
    Prior therapy considerationDocumented failure/intolerance/contraindication to high‑dose PPI therapy
    Asthma eosinophil threshold
    Blood eosinophil threshold>= 150 cells/microliter
    Associated requirementEosinophilic phenotype documented in asthma intake

    Submission Requirements and Provider Responsibilities

    Prior Authorization

    Prior authorization: complete medication, diagnosis, and dosing fields

    Specify the exact Dupixent product presentation being requested, the diagnosis and ICD‑10 code(s), dosing (indicate if induction dosing is required and provide induction details if applicable), maintenance quantity (number of pens/syringes) and requested day supply, member weight (kg) when requested, and complete provider/member identifying details on a separate form per medication submission.

    • Select one listed presentation: Dupixent 200mg/1.14ml syringe; Dupixent 300mg/2ml pen; Dupixent 200mg/1.14ml pen; (document also lists Dupixent 30Omg/zml syringe as printed).
    • Enter diagnosis and ICD‑10 code(s).
    • Indicate whether induction dosing is required and provide induction regimen if applicable.
    • Provide maintenance dosing: number of pens/syringes and requested day supply (28 days, 84 days, or Other with directions).
    • Include member weight in kilograms when requested on the dosing section.
    • Submit a separate completed form for each medication.

    Clinical Background

    Dupixent (dupilumab) is an anti‑IL‑4/IL‑13 monoclonal antibody requested on this form for multiple type‑2 inflammatory and eosinophilic conditions, including moderate‑to‑severe atopic dermatitis, moderate‑to‑severe asthma with eosinophilic phenotype, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyposis, prurigo nodularis, chronic obstructive pulmonary disease, and chronic spontaneous urticaria. The intake questions capture disease‑specific objective measures (for example, esophageal eosinophils, blood eosinophil count, FEV1, nasal polyp score, mMRC) and prior treatment history to support assessment of medical necessity for initiation or continuation of therapy.

    Scoring Systems and Scales

    Nasal Polyp Score — sum of right and left nostril scores (0-8)
    Nasal Polyp Score rangeSum of right and left nostril scores, range 0 to 8
    PurposeCharacterizes baseline bilateral nasal polyps for CRSwNP intake
    Related measureBaseline nasal congestion score (0 to 3) also requested
    mMRC dyspnea scale — modified Medical Research Council dyspnea scale for baseline functional disability
    mMRC dyspnea scaleModified Medical Research Council dyspnea scale used to assess baseline functional disability due to dyspnea
    Use in COPD intakeRequested as member's baseline functional disability measure for COPD assessment

    Dosing, Supply, and Initiation Requirements

    Dosing and supply

    Document dosing details on the prior authorization form; specify induction dosing if required and the requested maintenance quantity and day supply.

    Induction dosing flag: Does the member require induction dosing? (Yes/No)

    From induction dosing question on form

    Maintenance quantity: Number of pens/syringes requested for maintenance (enter numeric quantity)

    From maintenance dosing section on form

    Requested day supply selection: 28 days, 84 days, or Other (specify)28 or 84 days (options)

    From maintenance dosing day supply options on form

    Continuation and Response Documentation

    Continuation/response documentation

    For members previously treated with Dupixent, the form requires documentation of clinical response items to support continuation of therapy.

    Prior Dupixent response: If member has been on Dupixent, select applicable clinical responses such as reduced symptoms (disease-specific), histological remission for EoE (<15 eos/hpf), decreased rescue medication or oral corticosteroid use, decreased frequency of exacerbations or hospitalizations, improved pulmonary function (for example FEV1), reduction in nasal polyp score or nasal congestion, reduction in itch or number of nodules, improved exercise tolerance or delayed disease progression in COPD, or improvement in CSU symptomsEoE histological remission < 15 eos/hpf; asthma FEV1/bronchodilator criteria per intake

    Multiple response items captured across indication sections of the form

    Prior Therapy and Step Requirements

    IndicationPrior therapies to document failure/intolerance/contraindication
    Atopic dermatitisGeneric topical corticosteroid; generic topical tacrolimus; generic topical pimecrolimus; note ability to apply topicals (extensive BSA) or severely damaged skin if topicals not feasible
    Eosinophilic esophagitis (EoE)High‑dose proton‑pump inhibitor therapy (for example omeprazole or pantoprazole 80 mg/day) — document failure, intolerance, or contraindication
    AsthmaInadequate control on medium‑ or high‑dose inhaled corticosteroid plus at least 1 additional controller (e.g., LABA, leukotriene receptor antagonist, theophylline) — document failure/intolerance/contraindication; also record exacerbation history and eosinophilic phenotype per form
    Chronic rhinosinusitis with nasal polyposis (CRSwNP)Intranasal corticosteroid; 14‑day course of oral corticosteroids — document therapeutic failure, intolerance, or contraindication
    Prurigo nodularisOne generic topical corticosteroid — document therapeutic failure, intolerance, or contraindication; note inability to apply topicals due to BSA or severely damaged skin
    Chronic obstructive pulmonary disease (COPD)At least 3 months of triple therapy (LAMA + LABA + inhaled corticosteroid) — document inadequate symptom control or intolerance/contraindication
    Chronic spontaneous urticaria (CSU)Antihistamine at maximum recommended doses (for example cetirizine, desloratadine, levocetirizine) — document therapeutic failure, intolerance, or contraindication

    Quantity and Request Limits

    Dupixent quantity limits — number of pens/syringes per request documented on form
    Quantity per requestNumber of pens/syringes to be provided (requested on the maintenance dosing section)
    Day supply linkageRequested number of pens/syringes is documented alongside requested day supply (28 or 84 days)
    Form locationMaintenance Dosing — 'Number of pens/syringes' field on the form

    Site of Care and Submission Destination

    Note

    Site‑of‑care: no explicit restrictions; submit via SPECARE fax/mail

    The form does not impose a site‑of‑care restriction; submit standard prior authorization requests for Dupixent via the SPECARE fax or mail process noted on the form.

    • No explicit infusion center or site‑of‑care limitation is listed on the form.
    • Use the same fax (1‑866‑240‑8123) or mailing address (120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222) for submission.
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyDupixent (dupilumab) prior authorization request form coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form specifying Dupixent presentation, diagnosis/ICD‑10, dosing (induction and maintenance quantity/day supply) and required provider/member details to the specified fax or mailing address.
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific IntakeMedication Presentations, Key Clinical Thresholds, and SupplySubmission Requirements and Provider ResponsibilitiesClinical BackgroundScoring Systems and ScalesDosing, Supply, and Initiation RequirementsContinuation and Response DocumentationPrior Therapy and Step RequirementsQuantity and Request LimitsSite of Care and Submission Destination
    Exacerbation history
    At least 2 exacerbations requiring systemic corticosteroids in prior 12 months or 1 hospitalization
    FEV1 reversibility threshold requirement
    FEV1 bronchodilator reversibility>= 12% and >= 200 mL after albuterol
    Supporting spirometryPre‑bronchodilator FEV1 should be provided on form
    Clinical relevanceUsed to document reversible airflow obstruction for asthma intake
    Requested day supply options
    Day supply options28 days
    Day supply options84 days
    Alternate optionOther (specified by provider)
    Step Therapy

    Document prior therapy failures, intolerances, or contraindications

    For each indication, document therapeutic failure, intolerance, or contraindication to the prior therapies listed on the form (the form requires selecting applicable prior therapy failures/intolerances or contraindications).

    • Atopic dermatitis: failure or intolerance to a generic topical corticosteroid and/or generic topical tacrolimus or pimecrolimus, or documentation that topical therapy cannot be applied due to extent of BSA or severely damaged skin.
    • Eosinophilic esophagitis: failure, intolerance, or contraindication to high‑dose PPI therapy (e.g., omeprazole or pantoprazole 80 mg/day).
    • Chronic rhinosinusitis with nasal polyposis: failure, intolerance, or contraindication to intranasal corticosteroid and to a 14‑day course of oral corticosteroids.
    • Prurigo nodularis: failure, intolerance, or contraindication to one generic topical corticosteroid or inability to apply topicals due to BSA/severely damaged skin.
    • COPD: inadequate control despite at least 3 months of triple therapy (LAMA + LABA + ICS) or intolerance/contraindication to these agents.
    • Chronic spontaneous urticaria: failure, contraindication, or intolerance to antihistamines at maximum recommended doses (e.g., cetirizine, desloratadine, levocetirizine).
    Documentation Required

    Submission instructions: complete form, include physician address and signature, fax or mail

    Complete all sections of the form, include the prescribing physician’s address and signature, and fax or mail the completed form with supporting clinical documentation to the SPECARE contact shown on the form.

    • Submit a separate form for each medication.
    • Provide physician name, NPI, phone, fax, full address (including suite/building, city, state, zip), physician signature, and date.
    • Fax the completed form and clinical documentation to 1‑866‑240‑8123 or mail to: 120 Fifth Avenue, SPECARE, Pittsburgh, PA 15222.
    Denial Risk

    Risk of denial for incomplete or missing information; authorization/payment not guaranteed

    Missing or incomplete required information on the form may result in denial of the request; also note that authorization does not guarantee payment and payment is subject to member eligibility.

    • The submitting provider certifies information is true, accurate, and complete; incomplete or missing required information may lead to denial.
    • Payment is subject to member eligibility and authorization does not guarantee payment.
    FormatScore reported on form (mMRC score)
    Directions and member weight: Directions for use and member weight in kilograms must be provided on the form

    Member weight in kg is required per form fields